Literature DB >> 12401530

A population-based study of mortality among patients with atrial fibrillation or flutter.

Humberto Vidaillet1, Juan F Granada, P o-Huang Chyou, Karen Maassen, Mario Ortiz, Juan N Pulido, Param Sharma, Peter N Smith, John Hayes.   

Abstract

PURPOSE: To determine the mortality associated with atrial flutter and atrial fibrillation in the general population. SUBJECTS AND METHODS: Using the Marshfield Epidemiologic Study Area, a database that captures nearly all medical care and deaths among its 58,820 residents, we identified patients diagnosed with atrial flutter or atrial fibrillation from July 1, 1991, through June 30, 1995. Patients were followed prospectively and compared with a group of controls without these arrhythmias.
RESULTS: A total of 4775 person-years of follow-up were completed in 577 patients and 577 controls. Compared with controls, mortality among patients with atrial fibrillation or flutter was nearly 7.8-fold higher at 6 months (95% confidence interval [CI]: 4.1 to 15) and 2.5-fold higher (95% CI: 2.0 to 3.1; P < 0.0001) at the last follow-up (mean [+/- SD] of 3.6 +/- 2.3 years; range, 1 day to 7.3 years). At 6 months, mortality among patients with atrial flutter alone was somewhat greater than in controls and less than one third that of those with atrial fibrillation (with or without atrial flutter) (P = 0.02). At the last follow-up, however, mortality was greater among patients with atrial flutter (hazard ratio [HR] = 1.7; 95% CI: 1.2 to 2.6; P = 0.007), atrial fibrillation (HR = 2.4; 95% CI: 1.9 to 3.1; P < 0.0001), or both atrial arrhythmias (HR = 2.5; 95% CI: 1.9 to 3.3; P < 0.0001) when compared with controls in models that adjusted for cardiovascular risk factors.
CONCLUSION: In the general population, both atrial flutter and atrial fibrillation are independent predictors of increased late mortality. The relatively benign course during the 6-month period after the initial diagnosis of atrial flutter suggests that early diagnosis and treatment of these patients may improve their long-term survival.

Entities:  

Mesh:

Year:  2002        PMID: 12401530     DOI: 10.1016/s0002-9343(02)01253-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  56 in total

1.  Atrial fibrillation: an emerging epidemic?

Authors:  J S Steinberg
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

Review 2.  Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA).

Authors:  Robert T Greenlee
Journal:  Clin Med Res       Date:  2003-10

Review 3.  [Atrial fibrillation].

Authors:  M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

4.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

5.  Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.

Authors:  Russell A Wilke; Richard L Berg; Humberto J Vidaillet; Michael D Caldwell; James K Burmester; Michael A Hillman
Journal:  Clin Med Res       Date:  2005-11

6.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.

Authors:  David Conen; Claudia U Chae; Robert J Glynn; Usha B Tedrow; Brendan M Everett; Julie E Buring; Christine M Albert
Journal:  JAMA       Date:  2011-05-25       Impact factor: 56.272

Review 7.  Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?

Authors:  Annamaria Mascolo; Konrad Urbanek; Antonella De Angelis; Maurizio Sessa; Cristina Scavone; Liberato Berrino; Giuseppe Massimo Claudio Rosano; Annalisa Capuano; Francesco Rossi
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 8.  Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.

Authors:  Shu Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

Review 9.  Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation.

Authors:  Ramin Artang; Humberto Vidaillet
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 10.  The surgical treatment of atrial fibrillation.

Authors:  Anson M Lee; Spencer J Melby; Ralph J Damiano
Journal:  Surg Clin North Am       Date:  2009-08       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.